CN114377009A

CN114377009A - Application of SB216763 in preparation of anti-influenza virus medicine

Info

Publication number: CN114377009A
Application number: CN202011130882.5A
Authority: CN
Inventors: 郭颖; 唐克; 吴悠; 杨雅媚; 陈姝冰; 莘一婧; 陈盼盼
Original assignee: Institute of Materia Medica of CAMS
Current assignee: Institute of Materia Medica of CAMS
Priority date: 2020-10-21
Filing date: 2020-10-21
Publication date: 2022-04-22

Abstract

The invention belongs to the technical field of medicines, and discloses application of a compound SB216763 in preparation of anti-influenza virus medicines, in particular application of the compound SB216763 shown in a structural formula (I) and pharmaceutically acceptable salts thereof in preparation of medicines for preventing or treating influenza virus infection. And the combined application of the compound SB216763 and other antiviral drugs.

Description

Application of SB216763 in preparation of anti-influenza virus medicine

Technical Field

The invention belongs to the technical field of medicines, and particularly relates to application of a compound SB216763(CAS: 280744-09-4) in preparation of a medicine for preventing or treating influenza virus infection. The invention encompasses the use of compound SB216763, alone or in combination, in the prevention or treatment of influenza virus infection.

Background

Influenza virus (Influenza virus) is an important threat to global public health safety, and according to the statistics of the World Health Organization (WHO), about 5-10% of adults and 20-30% of children are infected with Influenza virus every year, wherein 300- "500-" of severe patients and about 25-50 "of people died [ Ziegler T, Mamahit A, Cox NJ:65years of inflenza Surverialance by a world health organization-associated with a coordinated global network. inflenza and other respiratory viruses (2018)12(5): 558-" 565 "). Influenza viruses belong to the Orthomyxoviridae family (Orthomyxoviridae) and are divided into four types, a, b, c and d, where influenza viruses of a, b and c can infect humans and cause respiratory diseases. Influenza a viruses have the widest prevalence and the greatest harm. Wherein in 1918 Spanish flu epidemics cause 5000 million deaths; however, the swine influenza virus epidemic in 2009 also caused about 57 million deaths worldwide [ First global animals of 2009h1n1 pandemic deleted by cdc-led collectives (2012), https:// www.cdc.go v/flu/spotlights/pandemic-animals.

Influenza viruses are spherical, about 80-120nm in diameter, enveloped viruses whose genome is a single-stranded, segmented RNA. Influenza A virus has a total of 8 RNAs encoding at least 10 viral proteins [ David M Knipe P, Peter M Howley, MD: Fields virology,6th edition.2.Lippincott Williams & Wilkins (LWW), (2013) ]. The influenza virus envelope is derived from the host cell membrane, upon which three viral proteins are embedded: hemagglutinin (HA), Neuraminidase (NA), and the M2 ion channel. Influenza a viruses are classified by HA and NA serology, and 18 kinds of HA and 10 kinds of NA are known, so there are theoretically 180 subtypes in total. Epidemiological data show that there are H1N1 subtypes (spanish influenza in 1918 and swine influenza in 2009), H2N2 subtypes (asian influenza in 1950), and H3N2 subtype (hong kong influenza in 1960) that have caused a massive lethal influenza epidemic.

Seasonal influenza occurs annually, except for influenza pandemics, which occur primarily in winter, most commonly caused by influenza a or b viruses, with H1N1 and H3N2 being more common. Symptoms following seasonal influenza include sudden fever, coughing (usually dry), headache, muscle and joint pain, sore throat and runny nose. Coughing can be severe and can last for 2 weeks or more. Most people recover from fever and other symptoms within a week without the need for medical care. However, influenza can cause serious illness or death in high-risk populations. [ Ho w can I-influenced-shaping the fluorWorld Health Organization site: https:// www. who. int/new-room/q-a-detail/how-can-I-influenced-shaping-the-flu ]

The existing Anti-influenza virus Drugs include 7 types [ Amarelle L, Lecuona E, Sznajder JI: Anti-influenza treatment: Drugs currently used and under development. Archiv os de broncon immunology (2017)53(1):19-26. ]: the M2 ion channel inhibitors amantadine and rimantadine; the neuraminidase inhibitors oseltamivir, zanamivir, peramivir, and ranimivir; the CAP-dependent endonuclease inhibitor baloxavir (baloxavir marboxil). The 7 anti-influenza virus drugs have a commonality: they are drugs with influenza virus proteins as targets, so that when the targets are changed, the drug affinity is reduced, and the influenza virus escapes, thus becoming a drug-resistant virus. For example, the influenza M2 ion channel inhibitors amantadine and rimantadine have been used for a long time, and the WH O has not recommended amantadine and rimantadine for the treatment of influenza A virus [ Summary of influenz a antiviral survival details findings, septimber 2010-march 2011 ] https:// www.who.int/influenza/gisrs _ laboratory/update/antiviral _ survival/en/].

Although there are 7 anti-influenza drugs once or in use, there are 5-15 million people infected and ill worldwide each year. Statistics of the United states disease control center, 2010-2018, 930-4900 ten thousand influenza A virus infected patients and 1.2-7.9 ten thousand death each year [ Influnza (flu) (2020.). https:// www.cdc.gov/flu/about/burden/index. html ]; that is, after the anti-influenza virus drug supply and the injection of influenza virus vaccine, 5% -20% of all people still suffer from infection, which is mainly caused by the nature and variation of influenza virus and the recombination (reassoort) of its RNA genome. For example, neuraminidase inhibitors are the most commonly used drugs against influenza a viruses in the clinic, with oseltamivir (tamiflu) being the most widely used, and clinical data show that patients can only achieve better efficacy if they are dosed within 48 hours of viral infection [ Summary of influenza antiviral activity Summary definitions, Septemb er 2010-March 2011 (2011). ]. https:// www.who.int/influenza/gisrs _ laboratory/up dates/antiviral _ susceptibilities/en ].

The compound SB216763 is a GSK-3 (glycogen synthase kinase 3) inhibitor synthesized by SmithKline Beecham Pharmaceuticals, UK, and has a half inhibitory concentration against GSK-3 α of 34.3nM [ Coghlan MP, et al, selective small molecule inhibitors of glycerol synthase kinase-3 modulatory and gene transfer. chem Biol,2000, 7(10): 793-. Glycogen synthase kinase 3 plays an important role in the process of glycogen production, and glycogen synthase kinase 3 inhibits the activity thereof by phosphorylating glycogen synthase, plays an important role in the process of carbohydrate metabolism in the body, and is closely related to metabolic diseases such as diabetes and obesity, and neurodegenerative diseases such as alzheimer's disease. There are studies reporting that the compound SB216763 significantly reduces the death of central and peripheral neurons induced by the PI3K kinase pathway by inhibiting glycogen synthase kinase 3activity and by acting on Tau protein and β -catenin, substrates of glycogen synthase kinase 3, and plays a cytoprotective role for central or peripheral neurons [ Cross DA, et al, selective small-molecule inhibitors of glycerol synthase kinase-3activity detection primers for free neurons from problem. The compound SB216763 can improve the proliferation inhibition of the mouse hippocampal primary neuron stem cells by Saikosaponins-d, and play a role in cytoprotection [ Qin T, et al.modification of GSK 3beta/beta-catenin signaling on saikospon ins-d-induced inhibition of neural promoter cell proliferation and adut neural network.translation. 2019,424:152233 ]. Further studies have shown that compound SB216763 significantly increases the lifespan of Bleomycin (Bleomycin) -induced pulmonary inflammation and pulmonary fibrosis mice by inhibiting the production of inflammatory cytokines MCP-1 and TNF- α [ gureri C, et al, 3- (2,4-dichlorophenyl) -4- (1-methyl-1H-indole-3-yl) -1H-pyrolole-2, 5-dione (SB 216763), a glycerol synthase kinase-3inhibitor, display therapeutic properties in a mouse model of pulmonary inflammation and fibrosis, j pharmaceutical Exp Ther, 2010,332(3),785-7 ]. In addition, compound SB216763 can reduce lipopolysaccharide-induced oxidative stress and apoptosis in rat liver [ Sha J, et al. Dexmedetomidine expressed lipid-induced oxidative stress and cell apoptosis in rats by creating GSK-3 β/MKP-1/Nrf 2 pathway activity via the α 2 allergic receptor. toxin applied Phar major, 2019, 1; 364:144-152]. The compound SB216763 can also promote angiogenesis, anti-apoptosis and play a role in protecting a myocardial infarction model rat by up-regulating the expression of VEGF, Bcl-2and survivin [ K aga S, et al. Glycogen synthase kinase-3beta/beta-catenin proteins involved in the diagnosis of VEGF, Bcl-2and survivin expression in produced secreted myocard.2006, 40(1):138-47 ].

Research shows that the I type herpes simplex virus (HSV-1) can affect the synaptic function of neuron cells after infecting the neuron cells, so that the central nervous system is affected in functional lesion, and the I type herpes simplex virus is one of the causes of Alzheimer's disease. The compound SB216763 can reduce the accumulation of A beta protein in mouse cortical neuron and reduce the influence of HSV-1 infection on synaptic function by inhibiting the activity of glycogen synthase kinase, so that the pharmacological activity of the compound SB216763 is irrelevant to the direct inhibition or killing of HSV-1 virus. [ Piacentini R, et al, Herpes Simplex Virus ty pe-1infection indexes synthesis in concentrated chemical nerves GS K-3activation and endogenous analog-beta protein accumulation. Sci Rep.2015; 5:15444.]. Through literature search, no report about the anti-influenza virus activity of the compound SB216763 is found.

The invention applies an influenza virus infection model to evaluate the antiviral activity of the known compound/marketed medicine, and finds that the compound SB216763 has broad-spectrum anti-influenza virus activity and stronger inhibitory activity on influenza A and B virus infection. The data show that the compound SB216763 has the anti-influenza virus activity equivalent to that of a first-line antiviral drug ribavirin, wherein the anti-influenza A virus activity is stronger than that of ribavirin, and the compound SB216763 has good safety. The new application value of the compound SB216763 for resisting influenza virus is high, and the compound has application prospect. The invention relates to an invention patent about new application of a known compound.

Disclosure of Invention

The invention solves the technical problem of providing the application of a compound SB216763 and pharmaceutically acceptable salts thereof in preparing medicaments for preventing or treating influenza virus infection.

Specifically, in order to solve the technical problem of the present invention, the following technical scheme is adopted:

the first aspect of the technical scheme of the invention provides application of a compound SB216763 shown as a structural formula (I) and pharmaceutically acceptable salts thereof in preparing a medicament for preventing or treating influenza virus,

the pharmaceutically acceptable salt of the compound SB216763 comprises pharmaceutically acceptable organic salt or inorganic salt, wherein the organic salt comprises sulfonate, carboxylate, amino acid salt and fatty acid salt, and the inorganic salt comprises hydrochloride, bromate, iodate, sulfate, bisulfate, phosphate, hydrogenphosphate, dihydrogenphosphate and nitrate. Preferred are bisulfate, sulfate, hydrochloride and iodate salts.

The sulfonate comprises alkyl sulfonate containing 1-15 carbon atoms, benzene sulfonate, p-toluene sulfonate, o-toluene sulfonate and m-toluene sulfonate; carboxylates include tartrate, maleate, fumarate, citrate, malate, cinnamate, benzoate, malonate, succinate, glutarate, adipate, pamoate, and lactate; amino acid salts include glutamate, aspartate; the fatty acid salt comprises a long chain fatty acid salt having 2 to 18 carbon atoms.

Wherein the influenza virus comprises influenza A virus, influenza B virus, influenza C virus and influenza D virus.

The influenza A virus comprises an H1N1 subtype, an H1N2 subtype, an H2N2 subtype, an H2N3 subtype, an H3N1 subtype, an H3N2 subtype, an H3N8 subtype, an H5N1 subtype, an H5N2 subtype, an H5N3 subtype, an H5N6 subtype, an H5N8 subtype, an H5N9 subtype, an H6N1 subtype, an H6N2 subtype, an H7N1 subtype, an H7N2 subtype, an H7N3 subtype, an H7N4 subtype, an H7N7 subtype, an H7N9 subtype, an H9N2 subtype, an H10N7 subtype, an H10N8 subtype, an H11N2 subtype, an H11N9 subtype, an H17N10 subtype and an H18N 11 subtype. Wherein the influenza A virus H1N1 comprises A/Purtorico/8/1934, A/WSN/33, A/Hubei Hongshan/52/2005, A/Jingfang/262/1995, A/Guangdong Rou lake/219/2006 and A/FM/1/47 strains; the influenza A H3N2 virus includes A/Jiangxi east lake/312/2006, A/Jifang/15/90, A/Guangdong Fang/243/1972, A/Hanfang/359/1995, A/New York/238/2015, A/Brisbane/10/07, A/Perth/16/09 and A/Udorn/307/72 strains. Influenza B viruses include B/Jiangxi New/BV/39/2008, B/Jifang/13/1997, B/Shenzhen/155/2005, B/Sichuan/63/2001, B/Zhejiang/2/2001, B/Shandong/7/97, B/Durban/39/98, B/Shandong Taian Taishan/1219/2009, B/Sichuan/34/2001B/Yamagata/16/88, B/Victoria/2/87, B/Johannesburg/1/99 and B/Maputo/1/99 strains.

The second aspect of the technical scheme of the invention provides application of a pharmaceutical composition in preparing an anti-influenza virus medicament, which is characterized in that the pharmaceutical composition comprises a compound SB216763 shown in a structural formula (I) and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier or excipient; the pharmaceutical composition may also contain other antiviral agents

The pharmaceutical composition may be prepared according to methods well known in the art. The compounds of the invention may be formulated into any dosage form suitable for human or animal use by combining them with one or more pharmaceutically acceptable solid or liquid excipients and/or adjuvants.

The compounds of the present invention or pharmaceutical compositions containing them may be administered in unit dosage form by enteral or parenteral routes, such as oral, intravenous, intramuscular, subcutaneous, nasal, oromucosal, ophthalmic, pulmonary and respiratory, dermal, vaginal, rectal, and the like.

The dosage form for administration may be a liquid dosage form, a solid dosage form, or a semi-solid dosage form. The liquid dosage forms can be solution (including true solution and colloidal solution), emulsion (including o/w type, w/o type and multiple emulsion), suspension, injection (including water injection, powder injection and infusion), eye drop, nose drop, lotion, liniment, etc.; the solid dosage form can be tablet (including common tablet, enteric coated tablet, buccal tablet, dispersible tablet, chewable tablet, effervescent tablet, orally disintegrating tablet), capsule (including hard capsule, soft capsule, and enteric coated capsule), granule, powder, pellet, dripping pill, suppository, pellicle, patch, aerosol (powder), spray, etc.; semisolid dosage forms can be ointments, gels, pastes, and the like.

The compound can be prepared into common preparations, sustained release preparations, controlled release preparations, targeting preparations and various particle drug delivery systems.

For tableting the compounds of the invention, a wide variety of excipients known in the art may be used, including diluents, binders, wetting agents, disintegrants, lubricants, glidants. The diluent can be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.; the humectant can be water, ethanol, isopropanol, etc.; the binder can be starch slurry, dextrin, syrup, Mel, glucose solution, microcrystalline cellulose, acacia slurry, gelatin slurry, sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, ethyl cellulose, acrylic resin, carbomer, polyvinylpyrrolidone, polyethylene glycol, etc.; the disintegrant may be dry starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, crosslinked polyvinylpyrrolidone, crosslinked sodium carboxymethylcellulose, sodium carboxymethyl starch, sodium bicarbonate and citric acid, polyoxyethylene sorbitol fatty acid ester, sodium dodecyl sulfate, etc.; the lubricant and glidant may be talc, silicon dioxide, stearate, tartaric acid, liquid paraffin, polyethylene glycol, and the like.

The tablets may be further formulated into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer and multi-layer tablets.

To encapsulate the administration units, the active ingredient of the compounds of the invention can be mixed with diluents and glidants and the mixture can be placed directly into hard or soft capsules. Or the effective component of the compound of the invention can be prepared into granules or pellets with diluent, adhesive and disintegrating agent, and then placed into hard capsules or soft capsules. The various diluents, binders, wetting agents, disintegrants, glidants used to prepare the compound tablets of the present invention may also be used to prepare capsules of the compound of the present invention.

In order to prepare the compound of the invention into injection, water, ethanol, isopropanol, propylene glycol or a mixture thereof can be used as a solvent, and a proper amount of solubilizer, cosolvent, pH regulator and osmotic pressure regulator which are commonly used in the field can be added. The solubilizer or cosolvent can be poloxamer, lecithin, hydroxypropyl-beta-cyclodextrin, etc.; the pH regulator can be phosphate, acetate, hydrochloric acid, sodium hydroxide, etc.; the osmotic pressure regulator can be sodium chloride, mannitol, glucose, phosphate, acetate, etc. For example, mannitol and glucose can be added as proppant for preparing lyophilized powder for injection.

In addition, colorants, preservatives, flavors, or other additives may also be added to the pharmaceutical preparation, if desired.

The inventor of the invention finds that the compound SB216763 can block the infection of host cells by influenza virus. Can also be used in combination with other antiviral drugs.

For the purpose of administration and enhancing the therapeutic effect, the drug or pharmaceutical composition of the present invention can be administered by any known administration method.

The dosage of the pharmaceutical composition of the compound of the present invention to be administered may vary widely depending on the nature and severity of the disease to be prevented or treated, the individual condition of the patient or animal, the route and dosage form of administration, and the like.

The compounds or compositions of the present invention may be administered alone or in combination with other therapeutic or symptomatic agents. When the compound of the present invention is used in a synergistic manner with other therapeutic agents, the dosage thereof should be adjusted according to the actual circumstances.

Advantageous technical effects

The inventor of the invention finds that a GSK-3 inhibitor compound SB216763 has stronger inhibitory activity to influenza A and B virus infection by evaluating the anti-influenza virus infection activity of 300 known compounds per marketed drug, and data shows that the anti-influenza virus activity of the compound SB216763 is equivalent to that of a first-line antiviral drug ribavirin, wherein the anti-influenza A virus activity is stronger than that of ribavirin, and the compound SB216763 has good safety. The new application value of the compound SB216763 for resisting influenza virus is high, and the compound has application prospect.

Drawings

FIG. 1. evaluation of the Activity of the compound SB216763 to block infection of A549 cells by A/Puerto Rico/8/1934(H1N 1).

FIG. 2 shows the result of evaluating the activity of SB216763 compound in blocking A549 cell infection of A549 cell by A/east Jiangxi lake/312/2006 (H3N 2).

FIG. 3 shows the result of activity evaluation of the compound SB216763 for blocking new B/Jiangxi/BV/39/2008 infection of MDCK cells.

FIG. 4 Effect of SB216763 on A549 cell viability

FIG. 5 Effect of Compound SB216763 on MDCK cell viability

Detailed Description

Example 1 principle of detection of influenza Virus infection model

A/Puerto Rico/8/1934(H1N1), A/Jiangxi east lake/312/2006 (H3N2) and B/Jiangxi New construction/BV/39/2008 are classical seasonal influenza strains. Lung tissue is the major organ of influenza infection. The detection model mainly detects the inhibition effect of the compound on influenza A virus (A/Puerto Rico/8/1934 and A/Jiangxi east lake/312/2006) infected lung cancer A549 cells and the inhibition effect of the compound on B/Jiangxi new/BV/39/2008 infected MDCK cells.

The test model pre-incubates the compound and the cells for 20h before infection, then infects the cells with virus, tests the vitality of A549 cells 48h after infection, and calculates the inhibition rate of the compound on virus infection by comparing with the vitality of the cells of a solvent control group and normal cells which are not infected with the virus.

Example 2 principle of cell viability assay model

ATP plays an important role in various physiological processes of cells, directly provides energy for organisms, and is an important index reflecting cell activity and has positive correlation with the number of living cells. Therefore, the number of viable cells in the sample to be tested is reflected by the quantitative detection of ATP in the cell lysate.

The model adopts

The luminescence Assay Cell Viability Assay kit (Promega company) quantifies the Viability of A549 cells and MDCK cells by detecting ATP, and evaluates the influence of the compound on the Viability of the A549 cells and the MDCK cells.

Example 3 Experimental methods and results for A549 cell model infected with A/Puerto Rico/8/1934(H1N1)

A549 cells were plated at 4X 10 per well⁴The cells were inoculated in a 96-well plate, and after 4 hours, compound SB216763 was added to the cells to final concentrations of 30. mu.M, 10. mu.M, 3. mu.M and 1. mu.M, respectively, and no compound was added to the normal cell control group, and an equal volume of DMSO was added to the solvent control group, and the culture was continued for 20 hours. The medium was aspirated from the plates, the cells were rinsed once with PBS, infected with A/Puerto Rico/8/1934 virus A (M OI ═ 0.01), and incubated at 37 ℃ for 1 hour. The medium was aspirated off, rinsed once with PBS, and medium containing the test compound was added, normal cell control was added, and solvent control was added to medium containing equal amounts of DMSO. After 48 hours use

The cell viability was measured by luminometer cell viability assay kit (Promega corporation), i.e. relative luciferase activity (RLUs) in cell lysates was determined. The cellular morbidity and viral inhibition rate of each experimental group were calculated according to the formulas (1) and (2). Adopting GraphPad Prism software to analyze experimental data, taking the concentration-inhibition rate as a scatter diagram, obtaining a dose-effect curve by nonlinear fitting, and calculating the half effective concentration EC of the compound to be detected₅₀。

(1) The rate of cellular disease%_{Administration set}(or RLUs)_{Solvent control group})/RLUs_{Control group of Normal cells})×100％

(2) Percent virus inhibition (solvent control group cytopathic rate-administration group cytopathic rate)/solvent control group cytopathic rate × 100%

The results show that the compound SB216763 can block A/Puerto Rico/8/1934(H1N1) from infecting A549 cells, and the antiviral activity is better than that of the first-line antiviral drug ribavirin (the results are shown in Table 1, and the dose-effect curve is shown in figure 1).

TABLE 1 evaluation of Activity of Compounds on influenza A virus A/Puerto Rico/8/1934(H1N1) infected A549 cells

Example 4 Experimental methods and results for A549 cell model infected with A/east lake of Jiangxi/312/2006 (H3N2)

A549 cells were plated at 4X 10 per well⁴The cells were inoculated in a 96-well plate, and after 4 hours, compound SB216763 was added to the cells to final concentrations of 30. mu.M, 10. mu.M, 3. mu.M and 1. mu.M, respectively, and no compound was added to the normal cell control group, and an equal volume of DMSO was added to the solvent control group, and the culture was continued for 20 hours. The medium was aspirated from the plates, the cells were rinsed once with PBS, infected with A/east Jiangxi lake/312/2006 virus type A (M OI ═ 0.02), and incubated at 37 ℃ for 1 hour. The medium was aspirated off, rinsed once with PBS, and medium containing the test compound was added, normal cell control was added, and solvent control was added to medium containing equal amounts of DMSO. After 48 hours use

The result shows that the compound SB216763 can block A549 cell infection of A549 cell by A/Jiangxiang east lake/312/2006 (H3N2), and the antiviral activity is better than that of the first-line antiviral drug ribavirin (the result is shown in Table 2, and the dose-effect curve is shown in figure 2).

TABLE 2 evaluation of Activity of Compounds on influenza A Virus A/east Jiangxi lake/312/2006 (H3N2) infected A549 cells

Example 5 Experimental methods and results for B type B/Jiangxi New/BV/39/2008 infection MDCK cell model

MDCK cells were plated at 4X 10 per well⁴The cells were inoculated in a 96-well plate, and after 4 hours, compound SB216763 was added to the cells to final concentrations of 30. mu.M, 10. mu.M, 3. mu.M and 1. mu.M, respectively, and no compound was added to the normal cell control group, and an equal volume of DMSO was added to the solvent control group, and the culture was continued for 20 hours. The medium was aspirated off the plates, the cells were rinsed once with PBS, and type B/Jiangxi New/BV/39/2008 virus infection (100 × TCID)₅₀) Incubate at 37 ℃ for 1 hour. The medium was aspirated off, rinsed once with PBS, and medium containing the test compound was added, normal cell control was added, and solvent control was added to medium containing equal amounts of DMSO. After 48 hours use

The cell viability was measured by a luminescence cell viability assay kit (Promega corporation), which measures relative luciferase activity (RLUs) in cell lysates. The cellular morbidity and viral inhibition rate of each experimental group were calculated according to the formulas (1) and (2). Adopting GraphPad Prism software to analyze experimental data, taking the concentration-inhibition rate as a scatter diagram, obtaining a dose-effect curve by nonlinear fitting, and calculating the half effective concentration EC of the compound to be detected₅₀。

The result shows that the compound SB216763 can block newly established B/Jiangxi/BV/39/2008B from infecting MD CK cells, and the inhibitory activity is equivalent to that of ribavirin, a first-line antiviral drug (the result is shown in a table 3, and the dose-effect curve is shown in an attached figure 3).

Table 3 evaluation results of Activity of Compounds on influenza B virus B/Jiangxi New construction/BV/39/2008 infected MDCK

Example 6 examination of the Effect of Compounds on cell viability

A549 cells or MDCK cells were seeded at 8000 cells/well in 96-well plates at a cell density of 100. mu.L/well in cell liquid at 37 ℃ in 5% CO₂And culturing for 24 h. The following day different concentrations of test compound were added to the cells, with an equal amount of DMSO (0.1% v/v) as a solvent control. After further culturing for 48h, 100. mu.L of CellTiter-Glo reagent was added to each well, mixed well by shaking for 2min, incubated at room temperature for 10min, and RLUs [ Tang K, He S, Zhang X, et al, Tangeretin, an extract from cell cultures, blocks cellular entry of arenaviruses that are viral magnetic fields, antiviral Res.2018,160:87-93 were measured in each well.]. The cell viability of the drug-loaded wells was calculated using the DMSO solvent well RLUs values as 100%.

Percent cell viability-fluorescence intensity_{Administration set}Intensity of fluorescence_{Solvent control group}×100％。

The experimental results show that the compound SB216763 has no influence on the vitality of A549 cells and MDCK cells at the half effective concentration (the results are shown in tables 4 and 5, and the dose-effect curves are shown in figures 4 and 5).

Table 4 effect of compound SB216763 on a549 cell viability

Table 5 effect of compound SB216763 on MDCK cell viability

Claims

1. The application of a compound SB216763 shown as a structural formula (I) and pharmaceutically acceptable salts thereof in preparing medicaments for preventing or treating influenza virus infection;

2. the use according to claim 1, wherein the pharmaceutically acceptable salt comprises a pharmaceutically acceptable organic salt or inorganic salt, wherein the organic salt comprises a sulfonate, a carboxylate, an amino acid salt, and a fatty acid salt, and the inorganic salt comprises a hydrochloride, a bromate, an iodate, a sulfate, a hydrogen sulfate, a phosphate, a hydrogen phosphate, a dihydrogen phosphate, and a nitrate.

3. Use according to claim 2, characterized in that said sulfonates comprise alkylsulfonates containing 1-15 carbon atoms, benzenesulfonates, p-toluenesulfonates, o-toluenesulfonates, m-toluenesulfonates; carboxylates include tartrate, maleate, fumarate, citrate, malate, cinnamate, benzoate, malonate, succinate, glutarate, adipate, pamoate, and lactate; amino acid salts include glutamate, aspartate; the fatty acid salt comprises a long chain fatty acid salt having 2 to 18 carbon atoms.

4. An application of a pharmaceutical composition in preparing a medicament for preventing or treating influenza virus infection is characterized in that the pharmaceutical composition comprises a compound SB216763 shown in a structural formula (I) and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier or excipient,

5. the use according to claim 4, wherein said pharmaceutical composition further comprises an additional antiviral agent.

6. The use according to any one of claims 1 to 4, wherein said influenza virus comprises influenza A, influenza B, influenza C and influenza D.